GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (OTCPK:GNFTF) » Definitions » EV-to-EBITDA

Genfit (Genfit) EV-to-EBITDA : (As of May. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Genfit EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genfit's enterprise value is $218.20 Mil. Genfit's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Genfit's EV-to-EBITDA for today is .

The historical rank and industry rank for Genfit's EV-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest EV-to-EBITDA of Genfit was 0.83. The lowest was -88.37. And the median was -11.14.

GNFTF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.57
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Genfit's stock price is $2.95. Genfit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.741. Therefore, Genfit's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Genfit EV-to-EBITDA Historical Data

The historical data trend for Genfit's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit EV-to-EBITDA Chart

Genfit Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.62 -1.96 0.39 -7.53 -7.59

Genfit Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.53 - - -7.59

Competitive Comparison of Genfit's EV-to-EBITDA

For the Biotechnology subindustry, Genfit's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genfit's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genfit's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genfit's EV-to-EBITDA falls into.



Genfit EV-to-EBITDA Calculation

Genfit's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=218.200/0
=

Genfit's current Enterprise Value is $218.20 Mil.
Genfit's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genfit  (OTCPK:GNFTF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Genfit's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.95/-0.741
=At Loss

Genfit's share price for today is $2.95.
Genfit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.741.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Genfit EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genfit's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit (Genfit) Business Description

Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.